The CHK1 inhibitor MU380 significantly increases the
sensitivity of human docetaxel-resistant prostate cancer cells
to gemcitabine through the induction of mitotic catastrophe

J 2020

The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe

DRÁPELA, Stanislav, PrashantKumar KHIRSARIYA, Wytske M VAN WEERDEN, Radek FEDR, Tereza SUCHÁNKOVÁ et. al.

Basic information

Original name

The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe

Authors

DRÁPELA, Stanislav (203 Czech Republic, belonging to the institution), PrashantKumar KHIRSARIYA (356 India, belonging to the institution), Wytske M VAN WEERDEN (528 Netherlands), Radek FEDR (203 Czech Republic), Tereza SUCHÁNKOVÁ (203 Czech Republic), Diana BÍZOVA (203 Czech Republic), Jan ČERVENÝ (203 Czech Republic), Aleš HAMPL (203 Czech Republic, belonging to the institution), Martin PUHR (40 Austria), William R WATSON (372 Ireland), Zoran CULIG (372 Ireland), Lumír KREJČÍ (203 Czech Republic, belonging to the institution), Kamil PARUCH (203 Czech Republic, belonging to the institution) and Karel SOUČEK (203 Czech Republic, guarantor, belonging to the institution)

Edition

Molecular oncology, Hoboken, Wiley, 2020, 1574-7891

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10608 Biochemistry and molecular biology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 6.603

RIV identification code

RIV/00216224:14310/20:00116570

Organization unit

Faculty of Science

DOI

http://dx.doi.org/10.1002/1878-0261.12756

UT WoS

000548858200001

Keywords in English

castration-resistant prostate cancer; checkpoint kinase 1; docetaxel resistance; gemcitabine; mitotic catastrophe; MU380

Abstract

V originále

As treatment options for patients with incurable metastatic castration-resistant prostate cancer (mCRPC) are considerably limited, novel effective therapeutic options are needed. Checkpoint kinase 1 (CHK1) is a highly conserved protein kinase implicated in the DNA damage response (DDR) pathway that prevents the accumulation of DNA damage and controls regular genome duplication. CHK1 has been associated with prostate cancer (PCa) induction, progression, and lethality; hence, CHK1 inhibitors SCH900776 (also known as MK-8776) and the more effective SCH900776 analog MU380 may have clinical applications in the therapy of PCa. Synergistic induction of DNA damage with CHK1 inhibition represents a promising therapeutic approach that has been tested in many types of malignancies, but not in chemoresistant mCRPC. Here, we report that such therapeutic approach may be exploited using the synergistic action of the antimetabolite gemcitabine (GEM) and CHK1 inhibitors SCH900776 and MU380 in docetaxel-resistant (DR) mCRPC. Given the results, both CHK1 inhibitors significantly potentiated the sensitivity to GEM in a panel of chemo-naive and matched DR PCa cell lines under 2D conditions. MU380 exhibited a stronger synergistic effect with GEM than clinical candidate SCH900776. MU380 alone or in combination with GEM significantly reduced spheroid size and increased apoptosis in all patient-derived xenograft 3D cultures, with a higher impact in DR models. Combined treatment induced premature mitosis from G1 phase resulting in the mitotic catastrophe as a prestage of apoptosis. Finally, treatment by MU380 alone, or in combination with GEM, significantly inhibited tumor growth of both PC339-DOC and PC346C-DOC xenograft models in mice. Taken together, our data suggest that metabolically robust and selective CHK1 inhibitor MU380 can bypass docetaxel resistance and improve the effectiveness of GEM in DR mCRPC models. This approach might allow for dose reduction of GEM and thereby minimize undesired toxicity and may represent a therapeutic option for patients with incurable DR mCRPC.

Links

EF16_025/0007381, research and development project

Name: Preklinická progrese nových organických sloučenin s cílenou biologickou aktivitou

LM2015063, research and development project

Name: Národní infrastruktura chemické biologie (Acronym: CZ-OPENSCREEN)

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

DRÁPELA, Stanislav, PrashantKumar KHIRSARIYA, Wytske M VAN WEERDEN, Radek FEDR, Tereza SUCHÁNKOVÁ, Diana BÍZOVA, Jan ČERVENÝ, Aleš HAMPL, Martin PUHR, William R WATSON, Zoran CULIG, Lumír KREJČÍ, Kamil PARUCH and Karel SOUČEK. The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe. Molecular oncology. Hoboken: Wiley, 2020, vol. 14, No 10, p. 2487-2503. ISSN 1574-7891. Available from: https://dx.doi.org/10.1002/1878-0261.12756.

@article{1683057,
   author = {Drápela, Stanislav and Khirsariya, PrashantKumar and van Weerden, Wytske M and Fedr, Radek and Suchánková, Tereza and Bízova, Diana and Červený, Jan and Hampl, Aleš and Puhr, Martin and Watson, William R and Culig, Zoran and Krejčí, Lumír and Paruch, Kamil and Souček, Karel},
   article_location = {Hoboken},
   article_number = {10},
   doi = {http://dx.doi.org/10.1002/1878-0261.12756},
   keywords = {castration-resistant prostate cancer; checkpoint kinase 1; docetaxel resistance; gemcitabine; mitotic catastrophe; MU380},
   language = {eng},
   issn = {1574-7891},
   journal = {Molecular oncology},
   title = {The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe},
   url = {https://doi.org/10.1002/1878-0261.12756},
   volume = {14},
   year = {2020}
}

TY  - JOUR
ID  - 1683057
AU  - Drápela, Stanislav - Khirsariya, PrashantKumar - van Weerden, Wytske M - Fedr, Radek - Suchánková, Tereza - Bízova, Diana - Červený, Jan - Hampl, Aleš - Puhr, Martin - Watson, William R - Culig, Zoran - Krejčí, Lumír - Paruch, Kamil - Souček, Karel
PY  - 2020
TI  - The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe
JF  - Molecular oncology
VL  - 14
IS  - 10
SP  - 2487-2503
EP  - 2487-2503
PB  - Wiley
SN  - 15747891
KW  - castration-resistant prostate cancer
KW  - checkpoint kinase 1
KW  - docetaxel resistance
KW  - gemcitabine
KW  - mitotic catastrophe
KW  - MU380
UR  - https://doi.org/10.1002/1878-0261.12756
L2  - https://doi.org/10.1002/1878-0261.12756
N2  - As treatment options for patients with incurable metastatic castration-resistant prostate cancer (mCRPC) are considerably limited, novel effective therapeutic options are needed. Checkpoint kinase 1 (CHK1) is a highly conserved protein kinase implicated in the DNA damage response (DDR) pathway that prevents the accumulation of DNA damage and controls regular genome duplication. CHK1 has been associated with prostate cancer (PCa) induction, progression, and lethality; hence, CHK1 inhibitors SCH900776 (also known as MK-8776) and the more effective SCH900776 analog MU380 may have clinical applications in the therapy of PCa. Synergistic induction of DNA damage with CHK1 inhibition represents a promising therapeutic approach that has been tested in many types of malignancies, but not in chemoresistant mCRPC. Here, we report that such therapeutic approach may be exploited using the synergistic action of the antimetabolite gemcitabine (GEM) and CHK1 inhibitors SCH900776 and MU380 in docetaxel-resistant (DR) mCRPC. Given the results, both CHK1 inhibitors significantly potentiated the sensitivity to GEM in a panel of chemo-naive and matched DR PCa cell lines under 2D conditions. MU380 exhibited a stronger synergistic effect with GEM than clinical candidate SCH900776. MU380 alone or in combination with GEM significantly reduced spheroid size and increased apoptosis in all patient-derived xenograft 3D cultures, with a higher impact in DR models. Combined treatment induced premature mitosis from G1 phase resulting in the mitotic catastrophe as a prestage of apoptosis. Finally, treatment by MU380 alone, or in combination with GEM, significantly inhibited tumor growth of both PC339-DOC and PC346C-DOC xenograft models in mice. Taken together, our data suggest that metabolically robust and selective CHK1 inhibitor MU380 can bypass docetaxel resistance and improve the effectiveness of GEM in DR mCRPC models. This approach might allow for dose reduction of GEM and thereby minimize undesired toxicity and may represent a therapeutic option for patients with incurable DR mCRPC.
ER  -

DRÁPELA, Stanislav, PrashantKumar KHIRSARIYA, Wytske M VAN WEERDEN, Radek FEDR, Tereza SUCHÁNKOVÁ, Diana BÍZOVA, Jan ČERVENÝ, Aleš HAMPL, Martin PUHR, William R WATSON, Zoran CULIG, Lumír KREJČÍ, Kamil PARUCH and Karel SOUČEK. The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe. \textit{Molecular oncology}. Hoboken: Wiley, 2020, vol.~14, No~10, p.~2487-2503. ISSN~1574-7891. Available from: https://dx.doi.org/10.1002/1878-0261.12756.

Detailed Information on Publication Record